Exhibit Hall

HomeAttendeesExhibit Hall ▶ Industry Theaters
Industry Theaters

Sunday, May 20, 2018
Monday, May 21, 2018
Tuesday, May 22, 2018

Sunday, May 20, 2018

San Diego Convention Center

Mini Theater

11:30 AM - 12:00 PM


A Proven Long-Acting Muscarinic Antagonist for the Management of COPD

Speaker: Randall Brown MD, MPH, AE-C University of Michigan

Company: Sunovion Pharmaceuticals Inc.


12:30 PM - 01:00 PM


New evidence in COPD: is there consensus for clinical practice recommendations? (Open to International attendees only)

A faculty of experts (David Price [Singapore; moderator]; Ken Chapman [Canada]; Dave Singh [UK]) will discuss the new evidence informing the role of LABA/LAMA and LABA/LAMA/ICS therapy in COPD management. The importance of personalized COPD management will be discussed, including clinical considerations and consensus regarding use of ICS, and evidence-based approaches to ICS withdrawal. *An Industry Theater presentation at the ATS 2018 International Conference. This program is sponsored by Novartis Pharma AG. It is only available to attendees not from the United States.

Speakers: David Price M.B B.Chir, MA, DRCOG, FRCGP University of Aberdeen, UK; Observational and Pragmatic Research Institute, Singapore; Optimum Patient Care, Australia, Singapore, and UK ; Ken Chapman MSc, MD, FRCPC, FACP, FERS University of Toronto and Asthma and Airway Centre, University Health Network, Toronto Western Hospital, Toronto, Canada; Dave Singh BA, M.B B.Chir, MA, MRCP, MD University of Manchester and University Hospital Of South Manchester NHS Foundation Trust, Manchester, UK

Company: Novartis Pharma AG


01:30 PM - 02:00 PM


COPD Treatments, Exacerbations, and Relationship to Peripheral Blood Eosinophil Levels

COPD has diverse presentations, and the identification of patients who are most likely to respond to a given treatment should contribute to personalized care. Two considerations for selection of COPD treatments are symptoms and history of exacerbations. An additional consideration could include elevated peripheral blood eosinophil levels. Join a pulmonary expert to hear about COPD treatments, exacerbations, and how the levels of eosinophils, assessed as a continuous variable, could impact exacerbation rates.

Speaker: Dr. Mona Bafadhel Respiratory Medicine, University of Oxford

Company: AstraZeneca


Theater 1

11:30 AM - 12:15 PM


FASENRA™ (benralizumab) Subcutaneous Injection 30 mg: A Targeted Approach

You are cordially invited to attend a program to learn more about emerging mechanisms of disease and a treatment option for appropriate patients. By focusing on the underlying mechanism of disease, treatment can be tailored to the needs of individual patients. Join a national expert to explore the role of a targeted treatment option, its clinical efficacy and safety data, mechanism of action and tips for appropriate patient identification.

Speaker: Mario Castro MD, MPH Washington University School of Medicine

Company: AstraZeneca


01:15 PM - 02:00 PM


The Evolving Science of Asthma

Speaker: William J. Calhoun MD University of Texas Medical Branch

Company: Genentech and Novartis


Theater 2

11:30 AM - 12:15 PM


Fundamentals of IPF: Navigating the Patient Journey (Open to U.S. attendees only)

Join our expert physicians as they discuss how to tackle key challenges facing patients with idiopathic pulmonary fibrosis (IPF)—including how to ensure a prompt diagnosis and initiate a comprehensive management plan.

Speakers: Marilyn K. Glassberg MD University of Miami; Jonathan H. Chung MD University of Chicago

Company: Genentech, A Member of the Roche Group


01:15 PM - 02:00 PM


COPD and Treatment with Triple Therapy

This program will answer key questions about managing patients with COPD with triple therapy. It will explore challenges facing clinicians when managing COPD and review clinical safety and efficacy data.

Company: GSK


Monday, May 21, 2018

San Diego Convention Center

Mini Theater

11:30 AM - 12:00 PM


Lower Dose, Shorter Duration Therapy: OPTALYSE PE Trial – Acute and 1-Year Results

Treat bilateral Pulmonary Embolism with as little as 8 mg tPA total and in as little as 2-hours: • Identify which patients will benefit the most from this new lower dose, shorter duration therapy • Learn how PE patients’ Right Ventricular Dysfunction can be effectively treated in as little as 2 hours • Hear about the remarkable 1-year post-treatment results in efficacy, safety, and quality of life measures

Speaker: Gregory Piazza MD, MS Brigham and Women's Hospital

Company: BTG


12:30 PM - 01:00 PM


Cost-Effectiveness of Home Oxygen Therapy-Home Mechanical Ventilation (HOT-HMV) for Treatment of Chronic Obstructive Pulmonary Disease (COPD)

The potential health economic impact of HOT-HMV in the United States.

Speaker: Gerard J. Criner MD, FACP, FACCP Temple University

Company: Philips


Theater 1

11:30 AM - 12:15 PM


Inhaler Choice Matters in COPD: The Impact of Peak Inspiratory Flow on Drug Dispersion and Delivery from Inhalers

Company: Boehringer Ingelheim Pharmaceuticals, Inc.


01:15 PM - 02:00 PM


Looking to the future of COPD treatment: New evidence (Open to International attendees only)

The treatment goals of alleviating symptoms and reducing exacerbation risk in management of COPD remain unchanged but the updated guidelines give more clarity on which patients are suited for treatment with bronchodilators and which may require additional therapy. The industry theatre will focus on the importance of dual bronchodilator therapy (LAMA/LABA) for patients with persistent symptoms and will explore the latest evidence to support single inhaler triple therapy (ICS/LAMA/LABA) for patients with at least 1 moderate/severe exacerbation in the prior year. Adoption of these recommendations allows physicians to use a more personalised treatment approach for their COPD patients.

Speakers: Chris Cooper BSc, MB, BS, MD(Lond), MD(ECFMG), MS, FRCP, FACSM, FCCP, Professor Global Respiratory Franchise, GSK, US; Bernardino Alcazar Navarrete MD Hospital de Alta Resolución de Loja, Granada, Spain; Jean Bourbeau MD, MSC, FRCPC, Professor McGill University Montreal, Quebec, Canada; Chris Cooper BSc, MB, BS, MD(Lond), MD(ECFMG), MS, FRCP, FACSM, FCCP, Professor Global Respiratory Franchise, GSK, US

Company: GSK


Theater 2

11:30 AM - 12:15 PM


New Evidence in Treating Severe Eosinophilic Asthma With Targeted Therapy

Eosinophils are a known contributor to asthma exacerbations. Reducing exacerbations is the key objective when treating patients with severe asthma. Questions remain regarding targeting blood eosinophils in patients with severe eosinophilic asthma who also have allergic markers. Come learn about new evidence from a targeted treatment that reduced the frequency of asthma exacerbations.

Speakers: Rohit Katial MD GSK Local Medical Expert; Jean-Pierre Llanos-Ackert MD GSK US Medical Affairs Lead

Company: GSK


01:15 PM - 02:00 PM


The First and Only Nebulized LAMA for COPD

Speaker: Brian Carlin MD, FCCP, FAARC Pittsburgh Critical Care Associates

Company: Sunovion Pharmaceuticals Inc.


Tuesday, May 22, 2018

San Diego Convention Center

Mini Theater

11:30 AM - 12:00 PM


What Do You Consider When Patients with COPD Classified as GOLD D Continue to Exacerbate

GSK US Medical Affairs invites you to an overview of COPD, which will include the risk and impact of exacerbations as well as concepts in airway inflammation. Guidance from the GOLD 2017 Report will also be discussed.

Speaker: Mark Forshag MD, MHA GSK

Company: GSK


01:30 PM - 02:00 PM


The importance of extrafine triple therapy in the management of COPD patients (Open to International attendees only)

This session will focus on the following key topics: - the relevance of small airways in COPD physiopathology - the role of ICS in COPD - the efficacy of extrafine BDP/FF/GLY combination. The 20' minutes speech will be followed by a Q&A session.

Speakers: Alberto Papi University of Ferrara; Brian J Lipworth Ninewells Hospital - University of Dundee

Company: Chiesi Farmaceutici S.p.A.


Theater 1

11:30 AM - 12:15 PM


Why Long-Acting Dual Bronchodilation Should Be Used in COPD

Speaker: Michael Zack MD, FACP, FCCP, FACSM

Company: Sunovion Pharmaceuticals Inc.


01:15 PM - 02:00 PM


Uncontrolled Asthma: Connecting Type 2 Inflammation to Airway Pathology

The primary objective of this session is to increase HCP understanding of Type 2 inflammation and how it contributes to airway pathology in asthma. Evidence supporting roles for Type 2 cytokines in epithelial and airway smooth muscle pathology including remodeling, fibrosis, mucus production and airway hyperresponsiveness will be discussed. How these pathological features contribute to airway narrowing, progressive (and possibly irreversible) lung function decline and asthma symptoms will be reviewed in the context of poor asthma control.

Company: Sanofi Genzyme & Regeneron


Theater 2

11:30 AM - 12:15 PM


Nucala▼(Mepolizumab): Treating Severe Eosinophilic Asthma Patients With Overlapping Phenotypes (Open to International attendees only)

The management of severe eosinophilic asthma patients who also exhibit an allergic phenotype is an important clinical question for physicians. To address this issue, this industry theatre will discuss a meta-analysis of mepolizumab use in patients eligible for omalizumab focusing on relevant biomarkers that may or may not be useful in predicting response in these patients with an overlapping phenotype. This will be followed by a discussion of new clinical data from the OSMO study that included patients with an overlapping phenotype not optimally controlled with omalizumab therapy. Together, this information will help physicians in their treatment decisions for severe eosinophilic asthma patients with an overlapping phenotype.

Speakers: Eugene Bleecker BA, MD University of Arizona College of Medicine, Tucson, Arizona, US; Neil Barnes MB, BS, FRCP Global Respiratory Franchise, GlaxoSmithKline, London, UK; Peter Howarth BSc (Hons), MBBS, DM. FRCP Global Respiratory Franchise, GlaxoSmithKline, London, UK; Eugene Bleecker BA, MD University of Arizona College of Medicine, Tucson, Arizona, US

Company: GSK


01:15 PM - 02:00 PM


The Salford Lung Study: Innovation in Asthma Research (Open to International attendees only)

This Industry Theatre uses data from SLS to investigate what features of a medicine may impact effectiveness and explores the contribution of effectiveness trials to treatment decisions. SLS asthma was an open-label randomized controlled trial conducted in UK primary care, which aimed to guide treatment choices by generating effectiveness and safety data in a population representative of everyday clinical practice. Subjects were initiated on Relvar▼(fluticasone furoate/vilanterol) or continued with usual care (inhaled corticosteroids [ICS] or ICS/long-acting β2-agonists) for 52 weeks; treatments could be adjusted at the prescriber’s discretion as per normal clinical practice.

Speakers: Neil Barnes MB, BS, FRCP Global Respiratory Franchise, GlaxoSmithKline, London, UK; Dave Leather MB ChB, FRCGP Global Respiratory Franchise, GlaxoSmithKline, London, UK. ; Nawar Bakerly MD, FRCP Salford Royal NHS Foundation Trust, Salford, UK; Neil Barnes MB, BS, FRCP Global Respiratory Franchise, GlaxoSmithKline, London, UK

Company: GSK